Myriad Genetics (MYGN) Cash from Investing Activities (2016 - 2026)
Myriad Genetics has reported Cash from Investing Activities over the past 17 years, most recently at -$6.0 million for Q4 2025.
- Quarterly Cash from Investing Activities fell 1.69% to -$6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$27.4 million through Dec 2025, down 130.25% year-over-year, with the annual reading at -$27.4 million for FY2025, 130.25% down from the prior year.
- Cash from Investing Activities was -$6.0 million for Q4 2025 at Myriad Genetics, up from -$6.2 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $291.0 million in Q3 2021 and troughed at -$41.3 million in Q1 2022.
- The 5-year median for Cash from Investing Activities is -$6.1 million (2025), against an average of $9.5 million.
- Year-over-year, Cash from Investing Activities skyrocketed 1601.75% in 2021 and then tumbled 1190.91% in 2022.
- A 5-year view of Cash from Investing Activities shows it stood at -$25.9 million in 2021, then crashed by 37.45% to -$35.6 million in 2022, then surged by 66.29% to -$12.0 million in 2023, then skyrocketed by 50.83% to -$5.9 million in 2024, then decreased by 1.69% to -$6.0 million in 2025.
- Per Business Quant, the three most recent readings for MYGN's Cash from Investing Activities are -$6.0 million (Q4 2025), -$6.2 million (Q3 2025), and -$6.9 million (Q2 2025).